A clinical case of the use of the selective janus kinase inhibitor upadacitinib in an adult patient with severe atopic dermatitis

DOI: https://dx.doi.org/10.18565/pharmateca.2023.8.122-125

E.V. Svechnikova, K.A. Fomin

1) Polyclinic № 1 of the Administrative Department of the President of the Russian Federation, Moscow, Russia; 2) Russian Biotechnological University, Moscow, Russia
Background. Atopic dermatitis (AD) is one of the most common chronic inflammatory skin diseases affecting both children and adults. Its effect on the patient largely correlates with the severity of the disease. Despite this, there is currently a high level of dissatisfaction with effective and safe systemic therapy. The immunological complexity of the pathogenesis of AD makes the suppression of Janus kinases a promising approach to treatment.
Description of the clinical case. This case report describes the successful use of upadacitinib, a selective oral Janus kinase 1 inhibitor, in a patient with severe AD. The drug demonstrated a rapid clinical response, good tolerance and ease of use. Our experience has confirmed that upadacitinib is an effective and safe treatment option for refractory forms of AD.

About the Autors

Corresponding author: Elena V. Svechnikova, Dr. Sci. (Med.), Head of the Department of Dermatovenereology and Cosmetology, Polyclinic № 1 
of the Administrative Department of the President of the Russian Federation; Professor at the Department of Skin and Venereal Diseases, Russian Biotechnological University; Moscow, Russia; elene-elene@bk.ru

Similar Articles

Бионика Медиа